- Trials with a EudraCT protocol (1,604)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,604 result(s) found.
Displaying page 28 of 81.
EudraCT Number: 2008-005806-38 | Sponsor Protocol Number: NO21884 | Start Date*: 2009-10-23 | ||||||||||||||||||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | ||||||||||||||||||||||||||||
Full Title: A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with a... | ||||||||||||||||||||||||||||
Medical condition: PIb: solid malignancy that is metastatic or unresectable PII: C 1: Advanced metastatic renal cell carcinoma C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancre... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006647-45 | Sponsor Protocol Number: D1060C00001 | Start Date*: 2009-05-14 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary ... | ||||||||||||||||||
Medical condition: Myeloproliferative disorders including Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000373-80 | Sponsor Protocol Number: DERM-101 | Start Date*: 2018-05-24 | ||||||||||||||||
Sponsor Name:Dermecular Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or H... | ||||||||||||||||||
Medical condition: Darier’s Disease or Hailey-Hailey Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002213-13 | Sponsor Protocol Number: 6 BT | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:Menarini Ricerche S.p.A. | |||||||||||||
Full Title: A Phase I/II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Systemic Absorption and Dihydropyrimidine Dehydrogenase (DPD) Enzyme Activity Following Re... | |||||||||||||
Medical condition: Herpes Simplex Labialis (HSL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003647-34 | Sponsor Protocol Number: AMLSG23-14/Palbo-AL-1 | Start Date*: 2015-05-19 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias | ||
Medical condition: Acute myeloid leukemia Acute lymphoblastic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004860-39 | Sponsor Protocol Number: TIGET-BTHAL | Start Date*: 2015-03-04 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment ... | |||||||||||||
Medical condition: Beta talassemia trasfusione dipendente | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002135-34 | Sponsor Protocol Number: IPH2201-201 | Start Date*: 2014-10-20 | |||||||||||||||||||||
Sponsor Name:Innate Pharma | |||||||||||||||||||||||
Full Title: Open label single arm Phase Ib-II study of pre-operative IPH2201 in patients with locally advanced resectable squamous cell carcinoma of the oral cavity | |||||||||||||||||||||||
Medical condition: Locally advanced resectable squamous cell carcinoma of the oral cavity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020832-20 | Sponsor Protocol Number: P06356 | Start Date*: 2010-08-13 |
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials | ||
Full Title: An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356) | ||
Medical condition: This study is going to be conducted in heathy volunteers. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013766-78 | Sponsor Protocol Number: CA191-004 | Start Date*: 2010-04-14 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 0... | ||||||||||||||||||
Medical condition: Advanced or Metastatic Her-2-positive Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) GB (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001044-38 | Sponsor Protocol Number: UMCN-AKF14.01 | Start Date*: 2014-07-28 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Center | |||||||||||||
Full Title: Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY) | |||||||||||||
Medical condition: Patients who are treated or will be treated with imatinib, who previously underwent major gastrectomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019214-25 | Sponsor Protocol Number: AXP-CT-001 | Start Date*: 2010-08-24 | ||||||||||||||||
Sponsor Name:Axcentua Pharmaceuticals AB | ||||||||||||||||||
Full Title: Safety, pharmacokinetics and efficacy of AXP107-11 in combination with standard gemcitabine (Gemzar®) treatment in patients with locally advanced or metastatic, unresectable, adenocarcinoma of the ... | ||||||||||||||||||
Medical condition: Histologically confirmed, unresectable, locally advanced or metastatic pancreatic cancer stage III-IV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004962-18 | Sponsor Protocol Number: GT-09 | Start Date*: 2006-02-27 |
Sponsor Name:ALK-Abelló A/S | ||
Full Title: A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of ALK Grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (wi... | ||
Medical condition: IgE mediated allergy (hay fever, rhinoconjunctivitis) to grass pollen (Timothy grass, Phleum pratense) with or without asthma. – Alergia mediada por IgE (Rinoconjuntivitis) a polen de gramíneas (Hi... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004149-16 | Sponsor Protocol Number: H3E-ES-S085 | Start Date*: 2005-02-16 |
Sponsor Name:Lilly S.A. | ||
Full Title: Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer | ||
Medical condition: Locally Advanced, non-Resectable or Metastatic Urothelial Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000402-67 | Sponsor Protocol Number: MT-03 | Start Date*: 2007-08-01 | |||||||||||
Sponsor Name:ALK-Abelló S.A | |||||||||||||
Full Title: Estudio multicéntrico, randomizado, doble ciego-placebo en Fase I para evaluar la seguridad en niños del liofilizado oral ALK de ácaros | |||||||||||||
Medical condition: Asma alérgica leve a moderada, mediada por IgE, (con o sin rinoconjuntivitis) a los ácaros del polvo doméstico | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000602-44 | Sponsor Protocol Number: NVB CA 03 P SP 102 B0 | Start Date*: 2004-09-28 |
Sponsor Name:Pierre Fabre Ibérica, S.A. | ||
Full Title: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado | ||
Medical condition: Advanced breast cancer (metastatic) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003829-16 | Sponsor Protocol Number: RV-MM-DSMM-0279 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:GMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH | |||||||||||||
Full Title: An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide... | |||||||||||||
Medical condition: relapsed multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018392-22 | Sponsor Protocol Number: 114182 | Start Date*: 2010-03-24 | |||||||||||
Sponsor Name:GlaxoSmithKline S.A. | |||||||||||||
Full Title: Estudio fase I, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna antigripal estacional trivalente (GSK2186877A) adyuvada con varias dosis de AS03, administrada en niñ... | |||||||||||||
Medical condition: Vacunación frente a la gripe A y B de niños sanos, de 6 a 35 meses, que no hayan recibido la vacunación antigripal con anterioridad. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004015-35 | Sponsor Protocol Number: CMM/EM/2008 | Start Date*: 2009-08-25 |
Sponsor Name:Fundación Progreso y Salud | ||
Full Title: ENSAYO CLÍNICO MULTICÉNTRICO FASE I/II ALEATORIZADO Y CONTROLADO CON PLACEBO, PARA EVALUACIÓN DE SEGURIDAD Y FACTIBILIDAD DE LA TERAPIA CON DOS DOSIS DISTINTAS DE CÉLULAS TRONCALES MESENQUIMALES AU... | ||
Medical condition: Pacientes con esclerosis múltiple secundariamente progresiva, que no responden adecuadamente a los tratamientos registrados. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005074-12 | Sponsor Protocol Number: 20070411 | Start Date*: 2009-03-04 | |||||||||||||||||||||
Sponsor Name:Amgen Inc | |||||||||||||||||||||||
Full Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Es... | |||||||||||||||||||||||
Medical condition: Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. --------------------... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
